A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome

Pharmacogenetics. 1995 Aug;5(4):255-8. doi: 10.1097/00008571-199508000-00011.

Authors

P Wolkenstein¹, V Carrière, D Charue, S Bastuji-Garin, J Revuz, J C Roujeau, P Beaune, M Bagot

Affiliation

¹ Department of Dermatology, Hôpital Henri-Mondor, Créteil, France.

PMID: 8528274
DOI: 10.1097/00008571-199508000-00011

No abstract available

Publication types

Comparative Study
Research Support, Non-U.S. Gov't

MeSH terms

Acetylation
Adolescent
Adult
Aged
Aged, 80 and over
Anticonvulsants / adverse effects*
Arylamine N-Acetyltransferase / genetics*
Arylamine N-Acetyltransferase / metabolism
Female
Genetic Predisposition to Disease
Genotype
Humans
Male
Middle Aged
Risk Factors
Stevens-Johnson Syndrome / chemically induced*
Stevens-Johnson Syndrome / epidemiology*
Stevens-Johnson Syndrome / genetics
Sulfonamides / adverse effects*
Trimethoprim, Sulfamethoxazole Drug Combination / adverse effects*

Substances

Anticonvulsants
Sulfonamides
Trimethoprim, Sulfamethoxazole Drug Combination
Arylamine N-Acetyltransferase